Skip to main content

Advertisement

SpringerLink
Log in

B-cell inhibitors as therapy for rheumatoid arthritis: An update

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

A revolution in the treatment of rheumatoid arthritis has occurred in recent years. This holds particularly true for B-cell-directed therapies for rheumatoid arthritis. The approval of rituximab for the treatment of rheumatoid arthritis has not only expanded the armamentarium of therapies for rheumatologists, but it has also led the way to better understanding of the biologic sequelae of these treatments as well as the potential to better understand the etiology of autoimmune diseases. This review updates the latest B-cell therapies in rheumatoid arthritis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gordon DA, Hastings DE: Clinical features of rheumatoid arthritis. In Rheumatology, 3rd edn. Edited by Hochberg MC, Silman AJ, Smolen JS, et al. Philadelphia: Mosby; 2004:765–780.

    Google Scholar 

  2. Silman AJ, Hochberg MC: Epidemiology of the Rheumatic Diseases, 2nd edn. Edited by Silman AJ, Hochberg MC, Cooper C, et al.: Oxford: Oxford University Press; 2001:31–71.

    Google Scholar 

  3. Wagner UG, Kurtin PJ, Wahner A, et al.: The role of CD8+ and CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol 1998, 161:6390–6397.

    PubMed  CAS  Google Scholar 

  4. Silverman GJ, Carson DA: Roles of B cells in rheumatoid arthritis. Arch Res Ther 2003, 5(Suppl 4):S1–S6.

    Article  Google Scholar 

  5. Shaw T, Quan J, Totoritis MC: B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003, 62(Suppl II):ii55–59.

    PubMed  CAS  Google Scholar 

  6. Tan SM, Xu D, Roschke V, et al.: Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982–992.

    Article  PubMed  CAS  Google Scholar 

  7. Pasare C, Medzhitov R: Control of B-cell responses by Toll-like receptors. Nature 2005, 438:364–368.

    Article  PubMed  CAS  Google Scholar 

  8. Rifkin IR, Leadbetter EA, Busconi L, et al.: Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 2005, 204:27–42.

    Article  PubMed  CAS  Google Scholar 

  9. Riley JK, Sliwkowski MX: CD20: A Gene in Search of a function. Semin Oncol 2000, 27(6 Suppl 12):17–24.

    PubMed  CAS  Google Scholar 

  10. Bubien JK, Zhou LJ, Bell PD, et al.: Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993, 121:1121–1132.

    Article  PubMed  CAS  Google Scholar 

  11. O’Keefe TL, Williams GT, Davies SL, et al.: Mice carrying a CD20 gene disruption. Immunogenetics 1998, 48:125–132.

    Article  PubMed  CAS  Google Scholar 

  12. Grillo-Lopez AJ: Rituximab: an insider’s historical prospective. Semin Oncol 2000, 27(6 Suppl 12):9–12.

    PubMed  CAS  Google Scholar 

  13. Maloney DG: Preclinical and phase I and II trials of rituximab. Semin Oncol 1999, 26(5 Suppl 14):74–78.

    PubMed  CAS  Google Scholar 

  14. Dorner T, Burmester GR: The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opinion Rheum 2003, 15:246–252.

    Article  Google Scholar 

  15. Browning JL: B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Reviews 2006, 5:564–576.

    Article  PubMed  CAS  Google Scholar 

  16. Edwards JC, Szczepanski L, Szechinski J, et al.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572–2581.

    Article  PubMed  CAS  Google Scholar 

  17. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment (DANCER study). Arthritis Rheum 2006, 54:1390–1400.

    Article  PubMed  CAS  Google Scholar 

  18. Cohen SB, Emery P, Greenwald MW, et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter randomized double-blind placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 53:2793–2806.

    Article  Google Scholar 

  19. Roll P, Palanichamy A, Kneitz C, et al.: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006, 54:2377–2386.

    Article  PubMed  CAS  Google Scholar 

  20. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC: Reconstitution of peripheral blood B Cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:613–620.

    Article  PubMed  CAS  Google Scholar 

  21. Leandro MJ, Cooper N, Cambridge G, et al.: Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 2007, 46:29–36.

    Article  PubMed  CAS  Google Scholar 

  22. Rouziere A, Kneitz C, Palanichamy A, et al.: Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. Arthritis Res Ther 2005, 7:R714–724.

    Article  PubMed  CAS  Google Scholar 

  23. Vos K, Thurlings RM, Rogier M, et al.: Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:772–778.

    Article  PubMed  CAS  Google Scholar 

  24. Lavie F, Miceli-Richard C, Ittah M, et al.: Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700–703.

    Article  PubMed  CAS  Google Scholar 

  25. Vallerskog T, Heimburger M, Gunnarsson I, et al.: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.

    Article  PubMed  Google Scholar 

  26. Cambridge G, Stohl W, Leandro MJ, et al.: Circulating levels of B lymphocyte simulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical response. Arthritis Rheum 2006, 54:723–732.

    Article  PubMed  CAS  Google Scholar 

  27. Genovese MC, Kaine JL, Kohen MD, et al.: Safety and clinical activity of ocrelizumab (a humanized antibody targeting CD20+ B cells) in combination with methotrexate (MTX) in moderate-severe rheumatoid arthritis (RA) patients (pts) (Phase I/II ACTION study) [abstract 6]. Arthritis Rheum 2006, 54(9 Suppl):S66.

    Google Scholar 

  28. Manning WC, Natarajan R, Rao T, et al.: Serum BAFF levels correlate with B cell depletion in patients with rheumatoid arthritis treated with ocrelizumab [abstract 7]. Arthritis Rheum 2006, 54(9 Suppl):S67.

    Google Scholar 

  29. Ostergaard M, Wiell C, Sierakowski S, et al.: HuMax-CD20, a novel fully human monoclonal IgG1 antibody in the treatment of rheumatoid arthritis [abstract 2122]. Arthritis Rheum 2006, 54(9 Suppl):S230.

    Google Scholar 

  30. Burge DJ, Shu C, Martin RW, et al.: TRU-15, a small modular immunopharmaceutical (SMIP) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis [abstract 463]. Arthritis Rheum 2006, 54(9 Suppl):S230.

    Google Scholar 

  31. McKay J, Chwalinska-Sadowska H, Boling E, et al.: Belimumab (BmAb), a fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Arthritis Rheum 2005, 52:S710–711.

    Article  Google Scholar 

  32. Stohl W, Chatham W, Weisman M, et al.: Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BlyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum 2005, 52:S444.

    Article  Google Scholar 

  33. Tak PP, Thurlings RM, Dimic A, et al.: A phase IIb study to investigate atacicpet (TACI-Ig) in patients with rheumatoid arthritis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Washington, DC; November 10–15, 2006.

  34. Fleischman R, Wei N, Shaw M, et al.: BR3-Fc Phase I study: safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects of a novel BR3-Fc fusion protein in patients with rheumatoid arthritis [abstract 461]. Arthritis Rheum 2006, 54(9 Suppl):S229.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Dartmouth Hitchcock Medical Center, One Medical Drive, Lebanon, NH, 03755, USA

    Daniel Albert

Authors
  1. Jennifer Kwan-Morley
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Albert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Albert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kwan-Morley, J., Albert, D. B-cell inhibitors as therapy for rheumatoid arthritis: An update. Curr Rheumatol Rep 9, 401–406 (2007). https://doi.org/10.1007/s11926-007-0064-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0064-4

Keywords

Search

Navigation